GSK - GSK plc
Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 808,139 shares of the pharmaceutical company's stock after selling 129,449 shares during the period. Bank of New York
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC GSK's first approval in lung cancer, part of a growing portfolio of targeted treatments LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.1 The approval comes ahead of the original target action date of 18 September 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug Designations.2 Jideytro, part of the portfolio from the recently completed acquisition of Nuvalent, Inc. 3, was developed to address key efficacy and/or tolerability challenges of treating ROS1-postive NSCLC. Its next-generation design aims to combine high target-selectivity, broad coverage of ROS1 resistance mutations and blood-brain barrier penetration to address disease in the brain.
GSK said on Wednesday the U.S. FDA has approved its drug for adults with a form of lung cancer who have previously received a targeted therapy.
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) trades at a 42% discount to pharma peers, despite resilient earnings projections through the dolutegravir patent cliff. The HIV franchise's shift to long-acting injectables, protected by new IP, is driving 30–44% growth and mitigating generic risk. Nuvalent acquisition brings two near-term oncology launches, expected to improve margins and offset dolutegravir LOE impact.
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.
GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.
GSK plc (NYSE:GSK) on Friday announced a pivotal update regarding its Phase 3 clinical program for camlipixant, revealing a strategic decision to halt further development for refractory chronic cough (RCC).
Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach without straining the profit and loss account.
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00 in cash for each share of Nuvalent that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate.
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from...
UBS expects investors to pay little attention to GSK PLC's (LSE:GSK, NYSE:GSK) second-quarter results, with focus shifting instead to a strategy update from new chief executive Luke Miels. The bank reiterated its 'neutra'l rating on GSK ahead of results and a capital markets day due on 28 July.